Pulmatrix presents iCALM clinical study results
The study concluded that iCALM is a novel inhaled therapeutic with a previously unexplored mechanism of action that can lead to better control of symptoms and lung function
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.